EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections

Dereje A Negatu iD, Wassihun Wedajo Aragaw, Julianna Cangialosi, Véronique Dartois iD, Thomas Dick iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.01655-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Dereje A Negatu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Oxazolidinones, Mycobacterium Infections, Nontuberculous, Tuberculosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New oxazolidinones are in clinical development for the treatment of tuberculosis and nontuberculous mycobacterial (NTM) infections, as a replacement for linezolid and tedizolid, which cause mitochondrial toxicity after prolonged treatment. Here, we carried out side-by-side measurements of mitochondrial protein synthesis inhibition and activity against clinically relevant mycobacterial pathogens of approved and novel oxazolidinones.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxazolidinonesMycobacterium Infections, NontuberculousTuberculosisHumansAnti-Bacterial AgentsLinezolidNontuberculous Mycobacteria

Stichwörter der Autor:innen

mitochondrial toxicitynontuberculous mycobacteriaoxazolidinonetuberculosis

Substanzen

Anti-Bacterial AgentsOxazolidinonesLinezolid

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
  • Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
  • Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA.

ORCID-Profile: Dereje A Negatu, Véronique Dartois, Thomas Dick

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Negatu, D. A., Aragaw, W. W., Cangialosi, J., Dartois, V., & Dick, T. (2023). Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01655-22

Vancouver

Negatu DA, Aragaw WW, Cangialosi J, Dartois V, Dick T. Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.01655-22

BibTeX
@article{Negatu2023,
  author = {Negatu, Dereje A and Aragaw, Wassihun Wedajo and Cangialosi, Julianna and Dartois, Véronique and Dick, Thomas},
  title = {Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.01655-22}
}
Kostenlos starten →